These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23909910)

  • 1. Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.
    Acker TM; Khatri A; Vance KM; Slabber C; Bacsa J; Snyder JP; Traynelis SF; Liotta DC
    J Med Chem; 2013 Aug; 56(16):6434-56. PubMed ID: 23909910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons.
    Swanger SA; Vance KM; Acker TM; Zimmerman SS; DiRaddo JO; Myers SJ; Bundgaard C; Mosley CA; Summer SL; Menaldino DS; Jensen HS; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2018 Feb; 9(2):306-319. PubMed ID: 29043770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct GluN1 and GluN2 Structural Determinants for Subunit-Selective Positive Allosteric Modulation of
    Strong KL; Epplin MP; Ogden KK; Burger PB; Kaiser TM; Wilding TJ; Kusumoto H; Camp CR; Shaulsky G; Bhattacharya S; Perszyk RE; Menaldino DS; McDaniel MJ; Zhang J; Le P; Banke TG; Hansen KB; Huettner JE; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2021 Jan; 12(1):79-98. PubMed ID: 33326224
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of a Dihydroquinoline-Pyrazoline GluN2C/2D-Selective Negative Allosteric Modulator of the
    D'Erasmo MP; Akins NS; Ma P; Jing Y; Swanger SA; Sharma SK; Bartsch PW; Menaldino DS; Arcoria PJ; Bui TT; Pons-Bennaceur A; Le P; Allen JP; Ullman EZ; Nocilla KA; Zhang J; Perszyk RE; Kim S; Acker TM; Taz A; Burton SL; Coe K; Fritzemeier RG; Burnashev N; Yuan H; Liotta DC; Traynelis SF
    ACS Chem Neurosci; 2023 Sep; 14(17):3059-3076. PubMed ID: 37566734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator.
    Khatri A; Burger PB; Swanger SA; Hansen KB; Zimmerman S; Karakas E; Liotta DC; Furukawa H; Snyder JP; Traynelis SF
    Mol Pharmacol; 2014 Nov; 86(5):548-60. PubMed ID: 25205677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Structure-Activity Relationship of a Tetrahydroisoquinoline Class of N-Methyl-d-Aspartate Receptor Modulators that Potentiates GluN2B-Containing N-Methyl-d-Aspartate Receptors.
    Strong KL; Epplin MP; Bacsa J; Butch CJ; Burger PB; Menaldino DS; Traynelis SF; Liotta DC
    J Med Chem; 2017 Jul; 60(13):5556-5585. PubMed ID: 28586221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel family of negative and positive allosteric modulators of NMDA receptors.
    Costa BM; Irvine MW; Fang G; Eaves RJ; Mayo-Martin MB; Skifter DA; Jane DE; Monaghan DT
    J Pharmacol Exp Ther; 2010 Dec; 335(3):614-21. PubMed ID: 20858708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators.
    Acker TM; Yuan H; Hansen KB; Vance KM; Ogden KK; Jensen HS; Burger PB; Mullasseril P; Snyder JP; Liotta DC; Traynelis SF
    Mol Pharmacol; 2011 Nov; 80(5):782-95. PubMed ID: 21807990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NMDA Receptors Containing the GluN2D Subunit Control Neuronal Function in the Subthalamic Nucleus.
    Swanger SA; Vance KM; Pare JF; Sotty F; Fog K; Smith Y; Traynelis SF
    J Neurosci; 2015 Dec; 35(48):15971-83. PubMed ID: 26631477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.
    Costa BM; Irvine MW; Fang G; Eaves RJ; Mayo-Martin MB; Laube B; Jane DE; Monaghan DT
    Neuropharmacology; 2012 Mar; 62(4):1730-6. PubMed ID: 22155206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits.
    Yi F; Rouzbeh N; Hansen KB; Xu Y; Fanger CM; Gordon E; Paschetto K; Menniti FS; Volkmann RA
    Neuropharmacology; 2020 Aug; 173():107971. PubMed ID: 31987864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure activity relationship of tetrahydroisoquinoline-based potentiators of GluN2C and GluN2D containing N-methyl-D-aspartate receptors.
    Santangelo Freel RM; Ogden KK; Strong KL; Khatri A; Chepiga KM; Jensen HS; Traynelis SF; Liotta DC
    J Med Chem; 2013 Jul; 56(13):5351-81. PubMed ID: 23627311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NMDA receptors containing GluN2C and GluN2D subunits have opposing roles in modulating neuronal oscillations; potential mechanism for bidirectional feedback.
    Mao Z; He S; Mesnard C; Synowicki P; Zhang Y; Chung L; Wiesman AI; Wilson TW; Monaghan DT
    Brain Res; 2020 Jan; 1727():146571. PubMed ID: 31786200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synaptic NMDA receptors in basolateral amygdala principal neurons are triheteromeric proteins: physiological role of GluN2B subunits.
    Delaney AJ; Sedlak PL; Autuori E; Power JM; Sah P
    J Neurophysiol; 2013 Mar; 109(5):1391-402. PubMed ID: 23221411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based discovery of antagonists for GluN3-containing N-methyl-D-aspartate receptors.
    Kvist T; Greenwood JR; Hansen KB; Traynelis SF; Bräuner-Osborne H
    Neuropharmacology; 2013 Dec; 75():324-36. PubMed ID: 23973313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators.
    Zimmerman SS; Khatri A; Garnier-Amblard EC; Mullasseril P; Kurtkaya NL; Gyoneva S; Hansen KB; Traynelis SF; Liotta DC
    J Med Chem; 2014 Mar; 57(6):2334-56. PubMed ID: 24512267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High sensitivity of cerebellar neurons to homocysteine is determined by expression of GluN2C and GluN2D subunits of NMDA receptors.
    Sibarov DA; Giniatullin R; Antonov SM
    Biochem Biophys Res Commun; 2018 Nov; 506(3):648-652. PubMed ID: 30454701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of AICP as a GluN2C-Selective
    Jessen M; Frederiksen K; Yi F; Clausen RP; Hansen KB; Bräuner-Osborne H; Kilburn P; Damholt A
    Mol Pharmacol; 2017 Aug; 92(2):151-161. PubMed ID: 28588066
    [No Abstract]   [Full Text] [Related]  

  • 19. Differential effect of NMDA receptor GluN2C and GluN2D subunit ablation on behavior and channel blocker-induced schizophrenia phenotypes.
    Shelkar GP; Pavuluri R; Gandhi PJ; Ravikrishnan A; Gawande DY; Liu J; Stairs DJ; Ugale RR; Dravid SM
    Sci Rep; 2019 May; 9(1):7572. PubMed ID: 31110197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Negative allosteric modulation of GluN1/GluN3 NMDA receptors.
    Zhu Z; Yi F; Epplin MP; Liu D; Summer SL; Mizu R; Shaulsky G; XiangWei W; Tang W; Burger PB; Menaldino DS; Myers SJ; Liotta DC; Hansen KB; Yuan H; Traynelis SF
    Neuropharmacology; 2020 Oct; 176():108117. PubMed ID: 32389749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.